For the quarter ending 2025-09-30, PHAT has $240,289K in assets. $662,823K in debts. $135,156K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 135,156 | 149,569 | ||
| Prepaid expenses and other current assets | 13,227 | 14,620 | ||
| Accounts receivable, net | 55,789 | 51,255 | ||
| Inventory | 3,611 | 3,431 | ||
| Total current assets | 207,783 | 218,875 | ||
| Property and equipment, net | 1,156 | 1,242 | ||
| Operating lease right-of-use assets | 2,694 | 873 | ||
| Restricted cash | 2,862 | 2,862 | ||
| Inventory, non-current | 24,101 | 24,675 | ||
| Other long-term assets | 1,693 | 1,693 | ||
| Total assets | 240,289 | 250,220 | ||
| Accounts payable | 1,075 | 4,008 | ||
| Accrued expenses | 65,349 | 64,296 | ||
| Accrued interest | 1,764 | 1,755 | ||
| Operating lease liabilities, current | 591 | 238 | ||
| Current portion of revenue interest financing liability | 24,344 | 21,526 | ||
| Total current liabilities | 93,123 | 91,823 | ||
| Long-term debt, net of discount | 207,093 | 205,139 | ||
| Revenue interest financing liability | 348,984 | 347,003 | ||
| Operating lease liabilities | 2,123 | 589 | ||
| Other long-term liabilities | 11,500 | 11,500 | ||
| Total liabilities | 662,823 | 656,054 | ||
| Common stock, 0.0001 par value authorized shares - 400,000,000 at september 30, 2025 and december 31, 2024 issued and outstanding shares - 71,043,149 and 68,518,238 at september 30, 2025 and december 31, 2024, respectively | 6 | 6 | ||
| Treasury stock - 19 shares at september 30, 2025 and december 31, 2024 | 0 | 0 | ||
| Additional paid-in capital | 1,040,570 | 1,027,297 | ||
| Accumulated deficit | -1,463,110 | -1,433,137 | ||
| Total stockholders' deficit | -422,534 | -405,834 | ||
| Total liabilities and stockholders' deficit | 240,289 | 250,220 | ||
Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. (PHAT)